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AbstrACt
background Genetic risk assessment for breast cancer and 
ovarian cancer (BCOC) is expected to make major inroads 
into mainstream clinical practice. It is important to evaluate 
the potential impact on women ahead of its implementation 
in order to maximise health benefits, as predictive genetic 
testing without adequate support could lead to adverse 
psychological and behavioural responses to risk disclosure.
Objective To examine anticipated health behaviour changes 
and perceived control to disclosure of genetic risk for BCOC 
and establish demographic and person-specific correlates of 
adverse anticipated responses in a population-based sample 
of women.
Design Cross-sectional quantitative survey study carried 
out by the UK Office for National Statistics in January and 
March 2014.
setting Face-to-face computer-assisted interviews 
conducted by trained researchers in participants’ homes.
Participants 837 women randomly chosen from 
households across the UK identified from the Royal Mail’s 
Postcode Address File.
Outcome measures Anticipated health behaviour change 
and perceived control to disclosure of BCOC risk.
results In response to a genetic test result, most women 
(72%) indicated ‘I would try harder to have a healthy 
lifestyle’, and over half (55%) felt ‘it would give me more 
control over my life’. These associations were independent of 
demographic factors or perceived risk of BCOC in Bonferroni-
corrected multivariate analyses. However, a minority of 
women (14%) felt ‘it isn’t worth making lifestyle changes’ and 
that ‘I would feel less free to make choices in my life’ (16%) 
in response to BCOC risk disclosure. The former belief was 
more likely to be held by women who were educated below 
university degree level (P<0.001) after adjusting for other 
demographic and person-specific correlates.
Conclusion These findings indicate that women in the UK 
largely anticipate that they would engage in positive health 
behaviour changes in response to BCOC risk disclosure.
IntrODuCtIOn
Advances in genetic technologies have led 
to the identification of gene mutations 
associated with an increased risk of devel-
oping breast cancer and ovarian cancer 
(BCOC). In addition to germline mutations 
in BRCA1 and BRCA2, which confer a very 
high lifetime risk of BCOC (39%–65% and 
11%–37%, respectively),1–3 a growing list of 
moderate-risk and lower-risk markers specific 
to each cancer type have been identified.4–10 
These influence cancer development in a 
larger proportion of the population despite 
small-effect sizes. It is anticipated that, in 
future, some moderate-risk markers will be 
included in existing panel tests used in clinical 
genetics practice.11–13 While high penetrance 
genes such as BRCA1 and BRCA2 confer a 
lifetime risk for cancer of 50% or greater, the 
lifetime risk for moderately penetrant genes 
ranges from 20% to 50%, and low penetrance 
genes are thought to have a limited effect.14 
To date, genetic testing of BRCA1 and 
BRCA2 is conducted in clinical practice only, 
in individuals with a strong family history or 
after a cancer diagnosis. However, it has been 
argued that this approach is likely to miss a 
strengths and limitations of this study
 ► Stratified random sampling, the ‘gold-standard’ for 
survey recruitment, was used in this study.
 ► The study reports on anticipated responses to 
genetic breast cancer and ovarian cancer (BCOC) 
risk information from a large general population 
sample of women living in the UK.
 ► The survey questions were broad and may have 
been interpreted differently by different participants.
 ► A general hypothetical scenario about receiving 
genetic BCOC risk information was used instead 
of asking participants to consider a hypothetical 
scenario of receiving a high-risk or low-risk genetic 
test result.
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substantial proportion of women at high risk (~30%), 
particularly if the family is small, the mutation was trans-
mitted through the paternal line or the individual has 
a number of lower-risk variants whose effects are addi-
tive.15–18 Given that genetic testing for BCOC risk can now 
be carried out at a relatively low cost, there have been 
calls to make it available on a population level, based on 
the premise that timely awareness of genetic risk would 
empower individuals to make informed decisions about 
cancer risk management, allow for early intervention and 
ultimately improve clinical outcomes.19 There is a drive 
from healthcare professionals to ‘mainstream’ genetic 
testing as part of routine cancer care in oncology services, 
aimed at improving diagnosis and providing individual-
ised treatment for patients (http://www. mcgprogramme. 
com/).20–23 BRCA1 and BRCA2 testing may be offered to 
women diagnosed with triple negative breast cancer, and 
information on genetic status is likely to influence clinical 
care and management of the patient and the family.24 25 
Moreover, genetic testing for BCOC susceptibility can 
already be purchased over the internet26 (www. 23andme. 
com; www. getcolor. com). The notion that individuals 
have a ‘right to know’ their genetic information has also 
gained traction in recent years.27–30
However, concerns persist about patient safety related 
to poor psychological adjustment following genetic risk 
disclosure. Studies investigating reactions to disclosure 
of BRCA status commonly do not find evidence for 
persistent negative psychological outcomes beyond 1 year 
after result disclosure.31–34 There is also some evidence 
suggesting that genetic test results indicating a higher risk 
of disease can lead to behaviour change such as uptake of 
breast and colorectal cancer screening,31 35 36 although two 
systematic reviews found no significant impact of genetic 
risk information on other behaviours37 38 including 
smoking, physical activity, use of medication or vitamins, 
diet, alcohol use and use of a sunscreen. However, genetic 
testing has hitherto only been performed in women with 
a strong family history of BCOC, so these results may 
not generalise to a population largely unaware of any 
increased risk.
Currently, one-to-one genetic counselling is strongly 
embedded within clinical genetic testing services, offering 
education and support throughout the process. If genetic 
testing were introduced on a population level, the 
current model of delivering genetic counselling would 
no longer be feasible. It has been argued that returning 
genetic risk test results for highly debilitating conditions 
such as BCOC without appropriate professional guidance 
would leave room for misinterpretation and uncertainty, 
increasing the risk of adverse psychological outcomes.39–42 
In recent years, research has begun to investigate new 
approaches of providing cancer genetic services. Main-
streaming genetic testing, by offering women with a 
diagnosis of ovarian cancer testing directly through the 
oncology clinic and providing post-test genetic coun-
selling via clinical genetics for those with a pathogenic 
variant, is one example.43 44 Research has found that 
mainstreaming genetic testing in this way can successfully 
reduce time and resources spent on the processes45 and 
does not appear to negatively affect patients’ psycholog-
ical well-being.46 Genetic counselling with patients and 
healthy family members via telephone or video consul-
tations instead of face-to-face genetic counselling has 
also been found to be feasible, and patients are generally 
satisfied.47–49 These new approaches to offering genetic 
testing and providing genetic counselling for cancer 
susceptibility may be advantageous in future if testing is 
offered to patients more widely.
Although a wealth of studies have investigated antici-
pated psychological reactions to disclosure of BCOC 
genetic risk in higher-risk groups,31 50 51 little is known 
about this issue in women unselected for family history. 
One qualitative study found that women in the UK would 
support the idea of genetic testing for risk of ovarian 
cancer because they expected it to trigger positive life-
style changes and provide a means of control over cancer 
development.52 However, in a similar study investigating 
attitudes towards genetic testing for breast cancer risk in 
the Netherlands, women were more ambivalent about 
disclosure of genetic risk; although there was recognition 
of the benefits of testing, some women were uncertain 
about their reactions to risk disclosure and the impact it 
would have on their lives.53
An early population-based survey investigated attitudes 
towards genetic testing for breast cancer among 836 
women living in Washington State.54 Results showed that 
over three quarters of the sample expected that aware-
ness of their genetic risk of breast cancer would give 
them more control over their life, and a similar number 
reported that they would ‘definitely’ or ‘probably’ take 
part in testing if it was offered to them. A more recent 
population-based study with over 800 participants in 
the Netherlands compared attitudes towards genetic 
testing between 2002 and 2010.55 Results showed that 
positive expectations about the utility of genetic testing 
had increased over the 8-year interval. However, about a 
third of participants believed that awareness of genetic 
risk would deprive people of the freedom to live as they 
want, and this proportion remained unchanged over 
time. Although these findings give an indication about 
the acceptability of population-based genetic testing, they 
may be culture-specific and may therefore not gener-
alise to other populations. Furthermore, the latter survey 
asked only about attitudes towards genetic testing more 
broadly; attitudes to genetic risk disclosure specific to 
BCOC may be different.
The aim of the present study was to examine the antic-
ipated health behaviour changes and perceived control 
in response to disclosure of genetic risk for BCOC and to 
explore demographic and person-specific correlates (eg, 
marital status and family history of cancer) of anticipated 
response among a population sample of women in the 
UK. Identifying subgroups who are more likely to antici-
pate a negative response to learning about their genetic 
risk of developing these cancers, before genetic testing is 
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integrated into mainstream healthcare (eg, by including 
it in current cancer screening programmes), gives scope 
for timely intervention to avoid further increasing dispar-
ities in healthcare.
MethODs AnD PrOCeDure
This quantitative study complied with the principles set 
out in the Declaration of Helsinki. As a population-based 
anonymous survey, it was exempt from ethical approval, 
in accordance with the guidelines set out by the Univer-
sity College London ethics committee for non-National 
Health Service research (http:// ethics. grad. ucl. ac. uk/ 
exemptions. php).
sample
Data were collected by the UK Office for National Statis-
tics (ONS) in their monthly survey which is conducted on 
behalf of a range of organisations (eg, government depart-
ments, non-governmental institutions and academic 
departments). Each month, 2010 households are identi-
fied from the Royal Mail’s Postcode Address File using 
stratified random probability sampling. Selected addresses 
are contacted up to eight times at different times and days 
of the week to maximise response rates. One person aged 
over 16 years from each household is randomly chosen to 
complete a computer-assisted face-to-face interview with 
trained researchers. Surveys commonly include a variety 
of different topics, making participation bias unlikely, 
although participants can opt out at any point. Questions 
on the ‘genetics and screening’ module were included in 
data collection waves in January and March 2014.
Measures
The ‘genes and cancer’ module was introduced with a 
short statement: ‘Genes contain the ‘instruction manual’ 
of life, called DNA. Genes are passed from parents to 
their children. Nowadays, it is possible to predict whether 
someone is likely to develop certain diseases by looking 
at their genes. This is called genetic testing’. No further 
information was given, as we were interested in women’s 
attitudes towards BCOC genetic testing based on their 
current understanding of it. Participants were asked 
several questions in relation to genetic testing for BCOC 
risk and attitudes on breast cancer screening (see online 
supplementary material for detail). Some of the findings 
have previously been published.56
Outcome variables
Anticipated reactions to learning about increased BCOC 
risk were assessed with statements ranging from posi-
tively framed outcomes such as the opportunity to exert 
personal control (‘If I knew my genetic risk of breast 
cancer and ovarian cancer, it would give me more control 
over my life’) or to pursue health behaviours aimed at 
mitigating risk (‘If I knew my genetic risk of breast cancer 
and ovarian cancer I would try harder to have a healthy 
lifestyle’), to more negatively framed outcomes such as 
curtailing freedom of choice (‘If I knew my genetic risk 
of breast cancer and ovarian cancer, I would feel less free 
to make choices in my life’) or the perceived futility of 
attempting behaviour change (‘If I knew my genetic risk 
of breast cancer and ovarian cancer, I would feel it wasn’t 
worth making lifestyle changes’). All items were scored 
on a 5-point Likert scale ranging from ‘strongly disagree’ 
to ‘strongly agree’ and were adapted from previous 
research.54 55
Predictor variables
Perceived risk of BCOC was each assessed with one ques-
tion ‘Compared with other women of your age, what do 
you think are your chances of getting breast [ovarian] 
cancer’ with response options of: ‘much lower than 
others’, ‘lower than others’, ‘the same as others’, ‘higher 
than others’ and ‘much higher than others’. Given that 
individual risk categories pertaining to much lower/
much higher perceived risk were small, perceived risk was 
grouped into three categories: ‘much lower/lower than 
others, ‘same as others’ and ‘higher/much higher than 
others’.
Age, ethnicity, educational attainment and marital 
status were derived using standard survey items (https:// 
tinyurl. com/ ya6gn2g6). Age was coded as ≤50 years vs 
>50 years to investigate any generational differences in 
anticipated reactions and attitudes. We chose 50 years 
as the cut-off point since public interest in the UK for 
genetic testing has been reported as being greatest for 
people aged 46–60 years,57 and we felt that the age of 50 
years, being close to the average age of menopause in 
the UK (which is 51 years), was a reasonable midpoint 
to assess generational effects. Ethnicity was classified 
as ‘White’ versus ‘ethnic minority’ because the indi-
vidual ethnic minority subgroups were small. Educa-
tional attainment was classified as university degree or 
equivalent versus below university degree level. Marital 
status was coded as married/cohabiting versus single/
widowed/divorced. Family history of any cancer was 
assessed with one question: ‘Have your mother, father, 
or any of your brothers or sisters, been diagnosed with 
cancer?’ with response options being ‘yes’, ‘no’ and 
‘don’t know’.
statistical analyses
We included women aged 18–74 years to reflect the popu-
lation to whom genetic testing for risk of BCOC would 
likely become available in the future. Statistical analyses 
were carried out using SPSS V.20.0 (SPSS). Descrip-
tive statistics were explored using frequency tables. We 
explored demographic (age, ethnicity and education) 
and person-specific predictors (marital status, family 
history of cancer, perceived risk of ovarian cancer and 
perceived risk of breast cancer) for each outcome vari-
able using χ2 tests. Multivariate logistic regression 
models were used to investigate the demographic and 
person-specific correlates of anticipated reactions to 
disclosure of personal BCOC risk. Bonferroni corrections 
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were employed in all multivariate analyses to correct for 
multiple testing, with α=0.0125.
results
Demographic and personal characteristics
Data for the current study were collected in two 
waves: January and March 2014. In the January wave, 
8% (n=166) of the 2010 selected households were 
not eligible because they were businesses or empty 
properties. Of 1844 eligible households, 9% (n=171) 
could not be contacted, and 33% (n=608) declined 
to take part in the ONS survey. In the March wave, 
1853 households were eligible (92%). Of those, 13% 
(n=237) could not be contacted, and 31% (n=578) 
chose not to take part. Therefore, the overall response 
rate was 57%, comparable to previous ONS surveys 
(ONS 2013; ONS 2012; http://www. ons. gov. uk/ ons/ 
index. html). The total female sample was n=1095.
After excluding participants with incomplete data 
for any of the outcome variables (n=120) or who were 
aged younger than 18 years or older than 74 years 
(n=138), the final sample for analysis consisted of 
837 women. Table 1 presents the demographic and 
personal characteristics of the sample. In common 
with other survey studies, education was higher in the 
sample than in the general population; other demo-
graphic characteristics were comparable to the UK 
population of women aged 18–74 years (ONS Census 
2011: http://www. ons. gov. uk/ ons/ guide- method/ 
census/ 2011/ index).
Although 36.4% (n=305) of the sample reported a 
family history of any cancer, most women felt that they 
were not particularly at risk of breast or ovarian cancer; 
only 9.9% (n=83) thought that they were at ‘higher’ or 
‘much higher’ than average risk of breast cancer, and even 
fewer (7.6%, n=64) thought that they were at ‘higher’ or 
‘much higher’ risk of ovarian cancer. A full breakdown 
of responses can be found in the online supplementary 
material table 1.
support of genetic testing
Overall, women were supportive of the idea of genetic 
testing for breast and ovarian cancer. Only 2.0% 
(n=18) thought that it was ‘never’ a good time to have 
a genetic test. However, about a third of the sample 
(31.4%, n=290) were ‘unsure’. Opinions were divided 
on when the best time would be to get tested, with 
8.3% (n=77) thinking that it would be ‘just after 
birth’, just over a quarter (27.4%, n=253) thought 
‘during school’, 10.6% (n=98) reported ‘just before 
marriage’, 16.9% (n=156) said ‘before they plan to 
have a child’ and 3.4% (n=31) thought the best time 
would be ‘when they are unwell’. There were no 
demographic or personal correlates with ‘ever’ versus 
‘never’ supporting genetic testing for breast and 
ovarian cancer (data not shown).
Anticipated response to disclosure of genetic risk of breast 
and ovarian cancer
Overall, women anticipated to respond proactively to 
awareness of their genetic risk. Most (71.9%, n=669) 
said that they ‘would try harder to have a healthy life-
style’, and over half (54.7%, n=506) anticipated that it 




  Female 837 (100.0)
Age (mean, SD) 45.9 (15.5)
Age group
  18–29 years 143 (17.1)
  30–39 years 179 (21.4)
  40–49 years 160 (19.1)
  50–64 years 234 (28.0)
  65–74 years 121 (14.5)
Ethnicity
  White British 725 (86.6)
  White other 52 (6.3)
  Mixed ethnicity 12 (1.4)
  Black 11 (1.3)
  South Asian 28 (3.3)
  Other 9 (1.1)
Education
  No formal qualifications 126 (15.1)
  Less than degree level qualification 478 (57.1)
  Degree level (or equivalent) 233 (27.8)
Marital status
  Married/civil partnership/cohabiting 459 (54.8)
  Single 177 (21.1)
  Divorced/separated 140 (16.7)
  Widowed 61 (7.3)
Family history of cancer
(mother, father, brother and sister)
  Yes 305 (36.4)
  No/don’t know 532 (63.6)
Perceived chances of getting ovarian cancer 
compared with other women of same age
  Much higher/higher 64 (7.6)
  About the same as others 590 (70.5)
  Much lower/lower 183 (21.9)
Perceived chances of getting breast cancer 
compared with other women of same age
  Much higher/higher 83 (9.9)
  About the same as others 616 (73.7)
  Much lower/lower 137 (16.4)
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would give them ‘more control over my life’. However, 
a minority reported that it would ‘not be worth making 
lifestyle changes’ (14.1%, n=130) in response to genetic 
risk disclosure and that they would feel ‘less free to make 
choices in my life’ (16.4%, n=152).
In univariate analyses, there were no differences across 
demographic and person-specific variables in the expec-
tation that disclosure of genetic risk of BCOC would lead 
to increased personal efforts ‘to have a healthy lifestyle’ 
(table 2). Women who had fewer years of formal educa-
tion (χ2 (1)=4.57, P=0.032), were married (χ2 (1)=4.53, 
P=0.033) or had a family history of cancer (χ2 (1)=5.51, 
P=0.019) were significantly more likely to report that 
awareness of genetic risk would give them more control 
over their life (table 2). However, none of these associ-
ations remained after adjustment for covariates and 
multiple testing (table 3).
Women with fewer years of formal education were also 
significantly more likely to agree that ‘it wouldn’t be 
worth making lifestyle changes’ in response to genetic 
risk disclosure (χ2 (1)=7.17, P=0.007), and this associa-
tion remained in multivariate analyses (OR 1.99, 95% CI 
1.19 to 3.35, P=0.009). Women from ethnic minority 
backgrounds (χ2 (1)=4.18, P=0.041), those who perceived 
themselves at a (much) lower or (much) higher risk of 
breast cancer (χ2 (4)=11.08, P=0.026) or ovarian cancer 
(χ2 (4)=22.38, P<0.001) were more likely to report that 
awareness of genetic risk would make them ‘feel less free 
to make choices in their life’, but none of these findings 
were maintained after adjusting for demographic and 
person-specific factors and for multiple testing (table 3).
DIsCussIOn
This study investigated demographic and person-specific 
correlates of anticipated health behaviour changes and 
perceived control in response to disclosure of genetic risk 
of BCOC in a population-based sample of women in the 
UK.
Although our results suggested that most women did 
not expect to be negatively affected by knowing their 
genetic risk status for BCOC, women who had fewer 
years of formal education were nearly twice more likely 
to believe that ‘it would not be worth making lifestyle 
changes’ than those who had stayed in formal education 
for longer. This finding supports some earlier studies into 
genetic determinism (the idea that genetic make-up is 
more important than environmental impact for expres-
sion of diseases)58; although not all studies have found 
this link.54 59
However, the finding that women with fewer years of 
formal education are less likely to believe that lifestyle 
changes could be effective for cancer prevention also 
echoes studies that investigated attitudes towards cancer 
screening. These studies have found that women with 
lower socioeconomic status, which is linked to educational 
attainment and information literacy,60 were more likely 
to hold fatalistic attitudes towards cancer development. 
Fatalistic attitudes have in turn been implicated in lower 
levels of engagement with cancer screening.61 62 It is 
possible that women who do not believe in the curability 
of cancer per se are also more likely to report that ‘it 
wouldn’t be worth making lifestyle changes’ in response 
to disclosure of BCOC genetic risk, but because we did 
not assess beliefs about curability of BCOC, this hypoth-
esis remains speculative. Furthermore, research has 
shown that those with fewer years in education are less 
aware of cancer risk factors such as poor diet and phys-
ical inactivity.63 A lack of awareness that lifestyle affects 
a person’s risk of cancer would also help to explain why 
some participants may feel that ‘it wouldn’t be worth 
making lifestyle changes’. Although formal years of 
education do not equate with health literacy, which was 
not measured in this study, educational attainment is 
strongly associated with health literacy64 and can there-
fore serve as an indicator for health literacy. Given that 
there are already disparities in engagement with avail-
able means of early detection for cancer (eg, screening) 
across the population, with lower socioeconomic status 
groups less likely to engage,65 it will be vital to provide 
adequate education and information about the nature of 
genetic testing before it is introduced into mainstream 
healthcare. This point has also been highlighted by other 
commentators in the field.66 67 In addition, it is important 
that the public has a multifaceted view of cancer and is 
aware of genetic and non-genetic risk factors and ways to 
reduce risk despite genetic susceptibility.
Although previous studies in both higher-risk68 69 and 
population samples52 70 have shown that younger women 
are generally more positive towards genetic testing, we 
found no age differences in anticipated reactions towards 
BCOC genetic risk disclosure. It is interesting to specu-
late about the impact on our study respondents about 
the benefits of genetic testing as a result of the spike in 
media coverage that took place shortly before the survey 
responses were collected at the beginning of 2014. The 
well-known actress Angelina Jolie publicly announced her 
reasons for undergoing BRCA genetic testing and talked 
about how the knowledge that she carried a gene variant 
had enabled her to choose risk-reducing surgery (double 
mastectomy) to manage her increased risk of devel-
oping breast cancer. This celebrity revelation may have 
raised awareness of the potential benefits of breast (and 
ovarian) cancer genetic testing across all age groups,71 72 
which may at least partially account for the finding that 
older women were as positive about genetic testing as 
younger women.
We found no association between participants’ antici-
pated response to genetic risk disclosure and perceived 
risk of either breast or ovarian cancer. However, since few 
women considered themselves to be at ‘higher’ or ‘much 
higher’ than average risk of BCOC, sample sizes may have 
been too small to detect associations. Alternatively, these 
findings may suggest that UK women may have a more 
realistic understanding of their personal risk of BCOC 
compared with reports in previous studies from other 
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countries.73 74 Given that all survey items were closed 
questions, we could not investigate this finding in more 
depth, but this could be done in future research.
The strengths of this study are the approach to sampling 
(the sample was selected using stratified random sampling 
which is the gold standard of survey recruitment, and, 
therefore, self-selection is unlikely to have biased current 
findings) and the statistical adjustment for multiple 
testing, which gives confidence in the robustness of the 
findings. However, the study also had important limita-
tions. We only assessed anticipated responses to disclo-
sure of genetic risk of BCOC in general, not whether 
these differed in response to a hypothetical ‘higher’ or 
‘lower’ genetic risk. Although all questions have been 
used in previous research with different samples, with 
comparable findings, anticipated lifestyle changes and 
their perceived effectiveness could vary depending on the 
levels of risk conferred. Further research could explore 
whether attitudes to genetic risk disclosure of BCOC 
differ when considering different levels of risk. Second, 
because of survey constraints, we focused our investiga-
tion on a limited set of broad questions which could have 
been interpreted differently by participants. Questions 
therefore remain about exactly how respondents antic-
ipated changing their behaviour. Future research could 
investigate this topic with more in-depth questions.
Naturally, responses to ‘real’ disclosure of genetic risk 
information may be less positive than our results suggest; 
while most participants in this study anticipated making 
an effort to ‘have a healthy lifestyle’, research has shown 
that there is generally a ‘gap’ between intentions and 
actual behaviour.75 In addition, given that many individ-
uals have difficulty in accurately anticipating emotional 
reactions to life events,76 77 these findings can only give 
a broad indication about potential effects of disclosure 
of BCOC genetic risk. Since none of the questions were 
open-ended, we could not explore the origins of responses 
in more detail, but this could be done in future research. 
Finally, although ethnic distribution of the sample was in 
line with the overall population in the UK because ethnic 
minority subgroups were small, we were unable to conduct 
more detailed analyses to investigate whether attitudes to 
genetic testing differed among women of different ethnic 
minority backgrounds. It will be important to explore 
this in future research, particularly since a recent review 
found a significant lack of research investigating UK 
black and minority ethnic (BAME) group awareness and 
attitudes towards genetic testing for cancer risk.78 Reports 
that have involved UK BAME groups highlight low aware-
ness of the availability of genetic services and fear and 
stigma in relation to cancer genetics.79 80
Overall, findings from this study indicate that women in 
the UK are generally positive about the prospect of popu-
lation-based genetic testing for risk of BCOC. However, 
those with fewer years in education may be less positive. 
Given that there are already existing disparities in uptake 
of available means of early detection for breast cancer, 
careful planning is needed to avoid increasing these 
further. There are concerns in professional circles that 
predictive genetic testing without adequate support could 
lead to adverse psychological and behavioural responses 
to risk disclosure. Although the risk of psychological harm 
may in part be mitigated by self-selection into genetic 
testing,81 it will be vital to understand the origins of antic-
ipated negative responses and provide adequate educa-
tion and information about the nature of genetic testing 
before its integration into mainstream healthcare. This 
study provides evidence to suggest that before population 
genetic testing is made available, education is needed that 
is inclusive of people with different levels of information 
literacy. Further studies will be needed to evaluate educa-
tion approaches and their impact on women’s choices 
about whether to participate.
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